Girerd X, Mourad J J, Vaïsse B, Poncelet P, Mallion J M, Herpin D
Service d'endocrinologie métabolisme, hôpital de la Pitié-Salpétrière, 83, bd de l'hôpital, 75013 Paris.
Arch Mal Coeur Vaiss. 2003 Jul-Aug;96(7-8):750-3.
The study used a cross-sectional survey of the general population living in metropolitan France in April 2002. A national sample of 5,000 adults, representative of the French population, 15 years of age or older, received at their home a questionnaire mailed by SOFRES medical. The sample was designed to provide estimates of the prevalence of hypertension in the general population and in persons older than 60 years of age, a subgroup on which prevalence of treated cardiovascular risk factors is unknown in France. The questionnaire included questions related to diagnosis of hypertension, awareness of their usual BP, current SBP/DBP values, prescribed medicine for hypertension dyslipidemia and diabetes. In FLAHS 2002, a number of 3,499 (70%) questionnaires were suitable for analysis. Estimates of prevalence were standardized by the direct method to the age distribution of the French population given by the 1999 national French census (INSEE 2000). Analysis on 2,363 subjects older than 35 years and indicates that 35% are currently treated for one or more risk factor. Overall, 8,036,000 received antihypertensive medication, 1,877,000 were treated for diabetes and 6,074,000 for dyslipidemia. Prevalence of treated hypertension increased with age from from 4.2% (35-44 years) to 51.8% (> 75 years) and 70% of treated hypertensives were older than 60 years. Subjects treated for two risk factors were 3,201,000 and those treated for three risk factors were 640,000. The FLAHS 2002 represents the best available data to estimate the prevalence of treated patients for a cardiovascular risk factor in the general French population. Thirty-five percent of the population 35 years of age or older representing around 11 millions persons were taking medications for the treatment of hypertension, diabetes or dyslipidemia in France.
该研究采用了2002年4月对居住在法国大都市的普通人群进行的横断面调查。一个由5000名15岁及以上成年人组成的全国性样本，代表法国人口，在家中收到了由索福瑞医疗公司邮寄的问卷。该样本旨在提供普通人群以及60岁以上人群中高血压患病率的估计值，法国对于60岁以上这一亚组人群中已治疗的心血管危险因素患病率尚不清楚。问卷包括与高血压诊断、对自身日常血压的知晓情况、当前收缩压/舒张压值、用于治疗高血压、血脂异常和糖尿病的处方药相关的问题。在2002年法国健康与生活方式调查（FLAHS 2002）中，有3499份（70%）问卷适合进行分析。患病率估计值通过直接法根据1999年法国全国人口普查（法国国家统计局，2000年）给出的法国人口年龄分布进行了标准化。对2363名35岁以上受试者的分析表明，35%的人目前正在接受一种或多种危险因素的治疗。总体而言，803.6万人接受了抗高血压药物治疗，187.7万人接受了糖尿病治疗，607.4万人接受了血脂异常治疗。治疗高血压的患病率随年龄增长从4.2%（35 - 44岁）升至51.8%（>75岁），且70%接受治疗的高血压患者年龄超过60岁。接受两种危险因素治疗的受试者有320.1万人，接受三种危险因素治疗的有64万人。2002年法国健康与生活方式调查代表了估算法国普通人群中接受心血管危险因素治疗患者患病率的最佳现有数据。在法国，35岁及以上的人群中有35%，约1100万人正在服用治疗高血压、糖尿病或血脂异常的药物。
